Assessment of joint pharmacokinetics and consequences for the intraarticular delivery of biologics

J Control Release. 2022 Aug:348:745-759. doi: 10.1016/j.jconrel.2022.06.015. Epub 2022 Jun 25.

Abstract

Intraarticular (IA) injections provide the opportunity to deliver biologics directly to their site of action for a local and efficient treatment of osteoarthritis. However, the synovial joint is a challenging site of administration since the drug is rapidly eliminated across the synovial membrane and has limited distribution into cartilage, resulting in unsatisfactory therapeutic efficacy. In order to rationally develop appropriate drug delivery systems, it is essential to thoroughly understand the unique biopharmaceutical environments and kinetics in the joint to adequately simulate them in relevant experimental models. This review presents a detailed view on articular kinetics and drug-tissue interplay of IA administered drugs and summarizes how these can be translated into reasonable formulation strategies by identification of key factors through which the joint residence time can be prolonged and specific structures can be targeted. In this way, pros and cons of the delivery approaches for biologics will be evaluated and the extent to which biorelevant models are applicable to gain mechanistic insights and ameliorate formulation design is discussed.

Keywords: Articular pharmacokinetics; Cartilage diffusion; Intraarticular injection; Joint residence time.

Publication types

  • Review

MeSH terms

  • Biological Products* / therapeutic use
  • Cartilage, Articular*
  • Drug Delivery Systems
  • Humans
  • Injections, Intra-Articular
  • Osteoarthritis* / drug therapy
  • Synovial Membrane

Substances

  • Biological Products